Structural Insights into Binding Specificity , Efficacy and Bias of Salmeterol , a Long-Acting β 2 Adrenergic Receptor Agonist

@inproceedings{Han2019StructuralII,
  title={Structural Insights into Binding Specificity , Efficacy and Bias of Salmeterol , a Long-Acting β 2 Adrenergic Receptor Agonist},
  author={Kyuho Han and Sarah L. Pierce and Amy Aisha. Li and Grace Leigh Anderson and Kaitlyn Spees and Jose A Seoane and Kaja Kostyrko and A F Mark and K Kelly and Peter R. Jackson and Alejandro Sweet-Cordero and Christina A. Curtis and Monte M Winslow and Michael C Bassik and Terry Hess and Laure Fr{\'e}sard and Cameron H. Lee and Karlene A Cimprich and Bahemuka Stephen and Montgomery and Ji-Hye Jung and Yuko Tada and Daniel von Bornstaedt and Siyeon Rhee and Young-Jun Jeon and Christine Wahlquist and Anthony and Cui Yu and Michelle R Santoso and Connor Tomas O’Brien and Kristy Red-Horse and Eric A Appel and Mark Mercola and Joseph Y. Woo and Phillip C Yang},
  year={2019}
}
Cell-based therapies are very sensitive to their environment and display intrinsic variability with potential sideeffects. That has resulted in tremendous costs of manufacturing and treatments. NeuroSyntekPharma CellOptimiser and CellDiagnostic systems reduce variability, enhance efficacy and minimize side effects. Our high-performance bioprocessing platforms aimed at integration, unification, and cost reduction of the cell processing pipelines. 

Similar Papers

Loading similar papers…